Summarize this paragraph. Do not mention the Mosquirix vaccine. 

The Matrix-M vaccine was approved in late 2022. It also targets the P. falciparum parasite. However, it contains a chemical substance that stimulates the body’s immune response. This makes it more effective than Mosquirix. The initial trial involved 450 children, aged 5-17 months. The children received three doses, followed by a booster a year later. The study found that the vaccine reduced the number of malaria cases by 80 percent.
user